Recombinant ArgF PLGA nanoparticles enhances BCG induced immune responses against Mycobacterium bovis infection

Mycobacterium bovis (M. bovis) is a member of mycobacterium tuberculosis complex (MTBC), and a causative agent of chronic respiratory disease in a wide range of hosts. Bacillus Calmette-Guerin (BCG) vaccine is mostly used for the prevention of childhood tuberculosis. Further substantial implications are required for the development and evaluation of new tuberculosis (TB) vaccines as well as improving the role of BCG in TB control strategies. In this study, we prepared PLGA nanoparticles encapsulated with argF antigen (argF-NPs). We hypothesized, that argF nanoparticles mediate immune responses of BCG vaccine in mice models of M. bovis infection. We observed that mice vaccinated with argF-NPs exhibited a significant increase in secretory IFN-gamma, CD4+ T cells response and mucosal secretory IgA against M. bovis infection. In addition, a marked increase was observed in the level of secretory IL-1 beta, TNF-alpha and IL-10 both in vitro and in vivo upon argF-NPs vaccination. Furthermore, argF-NPs vaccination resulted in a significant reduction in the inflammatory lesions in the lung's tissues, minimized the losses in total body weight and reduced M. bovis burden in infected mice. Our results indicate that BCG primeboost strategy might be a promising measure for the prevention against M. bovis infection by induction of CD4(+) T cells responses and mucosal antibodies.

Automated summary

The study showed that vaccination with argF nanoparticles enhanced immune responses against M. bovis infection in mice, leading to significantly reduced inflammatory lesions, decreased total body weight, and lower M. bovis burden in infected mice.